\"We expect emergency authorisation for Oxford-Astrazeneca vaccine to be sought in the UK. If so, it will give an opportunity for India regulator also (to consider such an option),\" says Dr Vinod Paul, chairman of the National Expert Group on Vaccine Administration for COVID-19

Bharat Biotech, the developer of India's indigenous vaccine Covaxin, has said that it is planning to enrol about 2,000 participants each in metros for Phase-3 trials of its COVID-19 vaccine that began earlier this week

The Hyderabad-based firm initiated phase I and phase II trials of its vaccine candidate after getting the green signal from the Drugs Controller General of India

Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year

As per Anthony Fauchi, the Pfizer's vaccine distribution process in the US will start in December. This, he said, will also help reduce the daily spike in coronavirus cases, which reached 1.9 lakh this week

Nirmala Sitharaman press conference: The minister said that the Rs 900 crore funding to the Department of Biotechnology will be for research purposes only

COVAXIN's phase-3 trial at AMU is aimed at checking the safety and effectiveness of the COVID-19 vaccine, jointly developed by the Hyderabad-headquartered Bharat Biotech, National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR)

Coronavirus vaccine: India will focus on these two vaccines as they are being tested on the Indian population and hence has a major advantage over other potential candidates

Share of Pfizer gained 19.46% to touch record high of Rs 5875 against previous close of Rs 4917 on BSE

Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology, was registered by the Russian Health Ministry

India may concentrate its efforts on Bharat Biotech's Covaxin as AstraZeneca's COVID-19 vaccine deliveries may be delayed. The months of November and December could be critical in terms of vaccine availability as a number of companies are likely to publish late-stage trial data

The company has taken on the development of Oxford University's potential COVID-19 vaccine, scoring billions in funding and signing multiple deals to supply over three billion doses to countries around the world

The Hyderabad-based company that has developed COVAXIN with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), had hoped to roll it out in the second quarter of 2021

Coronavirus vaccine update: Data compiled by Duke Global Health Innovation Center said that India has pre-ordered 600 million doses of coronavirus vaccine and is now in the process of negotiation for additional 1 billion doses

COVID-19 vaccine update: Based on the success of the trials and regulatory approvals, we can expect vaccine to be available in India by January 2021, only if its proven immunogenic and efficacious, says SII CEO Adar Poonawalla

German biotech firm CureVac has revealed its vaccine candidate has triggered an immune response during its phase 1 trials. The UK government has also started the process of the rolling review of AstraZeneca's candidate

Bharat Biotech Executive Director Sai Prasad said the price of the vaccine is yet to be determined, as the company is still looking at the cost of product development

Zydus Cadila's COVID-19 candidate vaccine ZyCov-D, which is currently undergoing second phase of clinical trials in India, is likely to enter Phase III final stage of clinical trials by December 2020

The outcome of immunogenicity blood tests conducted on a subgroup of older study participants echoed data published in July this year that revealed that the coronavirus vaccine produced robust immune responses in healthy adults aged 18-55 years

IMS and SUM Hospital is among the 21 medical institutes selected across the country by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted